High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.

Andrew J. Piper-Vallillo,Julia Rotow,Jacqueline V. Aredo,Khvaramza Shaverdashvili,Jia Luo,Jennifer W. Carlisle,Hatim Husain,Alona Muzikansky,Rebecca S. Heist,Deepa Rangachari,Suresh S. Ramalingam,Heather A. Wakelee,Helena Alexandra Yu,Lecia V. Sequist,Joshua Bauml,Joel W. Neal,Zofia Piotrowska

High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.

2020

Andrew J. Piper-Vallillo
Julia Rotow
Jacqueline V. Aredo
Khvaramza Shaverdashvili
Jia Luo
Jennifer W. Carlisle
Hatim Husain
Alona Muzikansky
Rebecca S. Heist
Deepa Rangachari
Suresh S. Ramalingam
Heather A. Wakelee
Helena Alexandra Yu
Lecia V. Sequist
Joshua Bauml
Joel W. Neal
Zofia Piotrowska

9586Background: High-dose osimertinib 160 mg QD (osi160) has activity in osi-naive, EGFR+ NSCLC pts with CNS or leptomeningeal disease (LMD) per the BLOOM trial, but the role of dose-escalation for...

Keywords:

Osimertinib
Oncology
Pathology
Internal medicine
Medicine
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations